Eterna Therapeutics
ERNA
7 hedge funds and large institutions have $2.51M invested in Eterna Therapeutics in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
24% less capital invested
Capital invested by funds: $3.31M → $2.51M (-$793K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$97.8K |
| 2 |
JP Morgan Chase
New York
|
-$3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $1.24M | – | – | – |
|
|
EAM
2
Eagle Asset Management
St Petersburg,
Florida
| $640K | – | – | – |
|
3
Renaissance Technologies
New York
| $148K | – | – | – |
|
4
Geode Capital Management
Boston,
Massachusetts
| $144K | – | – | – |
|
5
Goldman Sachs
New York
| $123K | – | – | – |
|
|
MHP
6
Manatuck Hill Partners
Westport,
Connecticut
| $95K | -$97.8K | -1 | -50% |
|
7
Vanguard Group
Malvern,
Pennsylvania
| $92K | – | – | – |
|
|
BIT
8
BlackRock Institutional Trust
San Francisco,
California
| $18K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $7K | – | – | – |
|
|
BFA
10
BlackRock Fund Advisors
San Francisco,
California
| $2K | – | – | – |
|
11
UBS Group
Zurich,
Switzerland
| $2K | – | – | – |
|
12
Barclays
London,
United Kingdom
| $1K | – | – | – |
|
|
IIC
13
Integrated Investment Consultants
Bloomfield Hills,
Michigan
| $1K | – | – | – |
|
|
LTFS
14
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | – | – | – |
|
15
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $1K | – | – | – |
|
|
16
JP Morgan Chase
New York
| – | -$3K | – | – |
|
ERNA Hedge Fund Activity: Q3 2016 in Review
7 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2016, worth a combined $2.51M — down 24% from $3.31M a quarter earlier.
Fund positioning in ERNA was balanced in Q3 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Manatuck Hill Partners, cutting an estimated $97.8K.
- 7 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $2.51M of Eterna Therapeutics stock for Q3 2016, down 24% quarter-over-quarter.
- 0 funds opened new Eterna Therapeutics positions in Q3 2016 and 0 closed out.
- The largest Eterna Therapeutics seller in Q3 2016 was Manatuck Hill Partners, an estimated $97.8K sold.
Based on aggregated 13F filings for Q3 2016.